Prevalence and Severity of Potential Drug-Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy.
Rx drugs
clinical decision support software
drug–drug interactions
multiple sclerosis
over-the-counter drugs
polypharmacy
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
08 Mar 2022
08 Mar 2022
Historique:
received:
31
01
2022
revised:
01
03
2022
accepted:
04
03
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
27
3
2022
Statut:
epublish
Résumé
Polypharmacy (PP) is a common problem in modern medicine, especially known to affect patients with chronic diseases such as multiple sclerosis (MS). With an increasing number of drugs taken, the risk of potential drug-drug interactions (pDDIs) is rising. This study aims to assess the prevalence and clinical relevance of polypharmacy and pDDIs in patients with MS. Pharmacological data of 627 patients with MS were entered into two drug-drug-interaction databases to determine the number and severity of pDDIs for each patient. The patients were divided into those with and without PP (total PP and prescription medication PP (Rx PP)). Of the 627 patients included, 53.3% and 38.6% had total PP and Rx PP, respectively. On average, every patient took 5.3 drugs. Of all patients, 63.8% had at least one pDDI with a mean of 4.6 pDDIs per patient. Less than 4% of all pDDIs were moderately severe or severe. Medication schedules should be checked for inappropriate medication and for possible interacting drugs to prevent pDDIs. Physicians as well as pharmacists should be more sensitive towards the relevance of pDDIs and know how they can be detected and avoided.
Identifiants
pubmed: 35335968
pii: pharmaceutics14030592
doi: 10.3390/pharmaceutics14030592
pmc: PMC8949310
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Rev Dis Primers. 2018 Nov 8;4(1):43
pubmed: 30410033
Toxicol Int. 2012 Jan;19(1):68-73
pubmed: 22736907
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Clin Pharmacol Ther. 2019 Jun;105(6):1395-1406
pubmed: 30912119
BMJ. 2001 Aug 25;323(7310):427-8
pubmed: 11520839
J Emerg Med. 2002 Feb;22(2):159-62
pubmed: 11858920
Fortschr Neurol Psychiatr. 2020 Jun;88(6):379-385
pubmed: 32557466
J Am Pharm Assoc (2003). 2008 Mar-Apr;48(2):203-214
pubmed: 18359733
Mult Scler. 2013 Jan;19(1):46-52
pubmed: 22711712
BMC Neurol. 2013 Sep 06;13:117
pubmed: 24011220
Mult Scler. 2020 Dec;26(14):1816-1821
pubmed: 33174475
Int J Clin Pharm. 2017 Oct;39(5):1119-1127
pubmed: 28795285
Expert Opin Drug Saf. 2020 Feb;19(2):139-145
pubmed: 31965869
Am Fam Physician. 2019 May 1;99(9):558-564
pubmed: 31038898
Pharmacoepidemiol Drug Saf. 2013 Feb;22(2):145-50
pubmed: 23097415
Expert Opin Pharmacother. 2018 Apr;19(5):483-498
pubmed: 29528247
Ther Adv Neurol Disord. 2020 Dec 19;13:1756286420969501
pubmed: 33425014
JAMA Intern Med. 2015 Jan;175(1):76-87
pubmed: 25401788
J Pharm Pharm Sci. 2012;15(2):332-43
pubmed: 22579011
Mult Scler. 2019 Oct;25(12):1641-1652
pubmed: 30230952
Am J Med. 2020 Dec;133(12):1380-1390.e2
pubmed: 32682869
J Neurol. 2008 Dec;255 Suppl 6:87-92
pubmed: 19300966
J Pharm Pharm Sci. 2009;12(3):266-72
pubmed: 20067703
Clin Med (Lond). 2016 Oct;16(5):465-469
pubmed: 27697812
Medicine (Baltimore). 2017 Sep;96(37):e8065
pubmed: 28906404
Curr Opin Neurol. 2020 Jun;33(3):286-294
pubmed: 32374570
Pharmacoepidemiol Drug Saf. 2014 May;23(5):489-97
pubmed: 24616171
Sci Rep. 2021 Jun 25;11(1):13340
pubmed: 34172792
Health Policy. 2011 Jul;101(2):153-61
pubmed: 21514685
Fam Pract. 1999 Jun;16(3):278-82
pubmed: 10439982
Expert Opin Drug Saf. 2014 Jan;13(1):57-65
pubmed: 24073682
Pharmacol Ther. 2013 Apr;138(1):103-41
pubmed: 23333322
Lancet. 2017 May 6;389(10081):1778-1780
pubmed: 28495154
Autoimmun Rev. 2012 Jan;11(3):159-62
pubmed: 21624507
Mult Scler. 2015 Mar;21(3):263-81
pubmed: 25623244
Int J Clin Pharmacol Ther. 2000 Nov;38(11):504-13
pubmed: 11097142
Fortschr Neurol Psychiatr. 2020 Jul;88(7):436-450
pubmed: 32717768
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
Am J Health Syst Pharm. 2006 Apr 15;63(8):744-7
pubmed: 16595815
Curr Pharm Des. 2021 Sep 20;:
pubmed: 34544336
Semin Neurol. 2016 Aug;36(4):350-6
pubmed: 27643903
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
BMC Geriatr. 2017 Oct 10;17(1):230
pubmed: 29017448
J Res Med Sci. 2013 Jul;18(7):601-10
pubmed: 24516494
Rev Lat Am Enfermagem. 2016 Sep 01;24:e2800
pubmed: 27598380
Indian J Crit Care Med. 2021 Nov;25(11):1226-1231
pubmed: 34866818
J Gerontol A Biol Sci Med Sci. 2006 May;61(5):511-5
pubmed: 16720750
CMAJ. 2005 Aug 30;173(5):510-5
pubmed: 16129874
Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648
pubmed: 34422112
Nervenarzt. 2018 Mar;89(3):319-326
pubmed: 28741067
J Pharm Sci. 2017 Sep;106(9):2214-2218
pubmed: 28435142
Thromb Res. 2012 Aug;130(2):147-51
pubmed: 22225858
Front Pharmacol. 2019 Apr 02;10:302
pubmed: 31001117
Ann Pharmacother. 2013 Oct;47(10):1272-9
pubmed: 24259691
Future Sci OA. 2020 May 29;6(8):FSO590
pubmed: 32983560
Res Social Adm Pharm. 2016 Jan-Feb;12(1):78-90
pubmed: 26004019
Arch Intern Med. 2002 May 27;162(10):1149-55
pubmed: 12020186
Brain. 2020 Dec 5;143(11):e97
pubmed: 33175163
Mult Scler Relat Disord. 2020 Nov;46:102485
pubmed: 32980646
Clinics (Sao Paulo). 2016 Jan;71(1):17-21
pubmed: 26872079
Neurotherapeutics. 2017 Oct;14(4):999-1017
pubmed: 28785958
Curr Pharm Des. 2021;27(38):4008-4016
pubmed: 34323180
J Am Pharm Assoc (2003). 2008 May-Jun;48(3):341-53
pubmed: 18595820
Qual Prim Care. 2014;22(4):177-87
pubmed: 25695529
BMJ Open. 2021 Sep 6;11(9):e052547
pubmed: 34489296